Involvement of asymmetric dimethylarginine (ADMA) in glomerular capillary loss and sclerosis in a rat model of chronic kidney disease (CKD)

Life Sciences

Volumn 84, Issue 23-24, 2009, Pages 853-856

  Ueda, Seiji ^a   Yamagishi, Sho ichi ^a   Matsumoto, Yuriko ^a   Kaida, Yusuke ^a   Fujimi Hayashida, Ayako ^a   Koike, Kiyomi ^a   Tanaka, Hideharu ^a   Fukami, Kei ^a   Okuda, Seiya ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

ADMA; Capillary; DDAH; Endothelium; Glomerular sclerosis; Nitric oxide

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDE; DIMETHYLARGININASE; HYDRALAZINE; N(G),N(G) DIMETHYLARGININE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; EXPERIMENTAL MODEL; EXPERIMENTAL RAT; GENE OVEREXPRESSION; GLOMERULUS CAPILLARY; NEPHRECTOMY; NONHUMAN; RAT; SCLEROSIS;

AMIDOHYDROLASES; ANIMALS; ARGININE; CAPILLARIES; DISEASE MODELS, ANIMAL; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY GLOMERULUS; RATS;

ADENOVIRIDAE; ANIMALIA; BACTERIA (MICROORGANISMS); RATTUS;

EID: 67349119848     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2009.03.018     Document Type: Article

References (25)

1. Baylis C. Nitric oxide deficiency in chronic kidney disease. American Journal of Physiology. Renal Physiology 294 1 (2008) F1-9
2. Cooke J.P. Dose ADMA cause endothelial dysfunction?. Arteriosclerosis, Thrombosis, and Vascular Biology 20 9 (2000) 2032-2037
3. Fliser D., Kronenberg F., Kielstein J.T., Morath C., Bode-Boger S.M., Haller H., and Ritz E. Asymmetric dimethylarginine and progression of chronic kidney disease: The mild to moderate kidney disease study. Journal of the American Society of Nephrology 16 8 (2005) 2456-2461
4. Jacobi J., Sydow K., von Degenfeld G., Zhang Y., Dayoub H., Wang B., Patterson A.J., Kimoto M., Blau H.M., and Cooke J.P. Overexpression of dimethylarginine dimethylaminohydrolase reduces tissue asymmetric dimethylarginine levels and enhances angiogenesis. Circulation 111 11 (2005) 1431-1438
5. Kang D.H., Nakagawa T., Feng L., and Johnson R.J. Nitric oxide modulates vascular disease in the remnant kidney model. The American Journal of Pathology 161 1 (2002) 239-248
6. Konishi H., Sydow K., and Cooke J.P. Dimethylarginine dimethylaminohydrolase promotes endothelial repair after vascular injury. Journal of the American College of Cardiology 49 10 (2007) 1099-1105
7. Lee L.K., Meyer T.W., Pollock A.S., and Lovett D.H. Endothelial cell injury initiates glomerular sclerosis in the rat remnant kidney. The Journal of Clinical Investigation 96 2 (1995) 953-964
8. Masuda Y., Shimizu A., Mori T., Ishiwata T., Kitamura H., Ohashi R., Ishizaki M., Asano G., Sugisaki Y., and Yamanaka N. Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis. The American Journal of Pathology 159 2 (2001) 599-608
9. Matsuguma K., Ueda S., Yamagishi S., Matsumoto Y., Kaneyuki U., Shibata R., Fujimura T., Matsuoka H., Kimoto M., Kato S., Imaizumi T., and Okuda S. Molecular mechanism for elevation of asymmetric dimethylarginine (ADMA) and its role for hypertension in chronic kidney disease. Journal of the American Society of Nephrology 17 8 (2006) 2176-2183
10. Matsumoto Y., Ueda S., Yamagishi S., Matsuguma K., Shibata R., Fukami K., Matsuoka H., Imaizumi T., and Okuda S. Dimethylarginine dimethylaminohydrolase prevents progression of renal dysfunction by inhibiting loss of peritubular capillaries and tubulointerstitial fibrosis in a rat model of chronic kidney disease. Journal of the American Society of Nephrology 18 5 (2007) 1525-1533
11. Matsuoka H., Itoh S., Kimoto M., Kohno K., Tamai O., Wada Y., Yasukawa H., Iwami G., Okuda S., and Imaizumi T. Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension. Hypertension 29 1 Pt 2 (1997) 242-247
12. Miyazaki H., Matsuoka H., Cooke J.P., Usui M., Ueda S., Okuda S., and Imaizumi T. Endogenous nitric oxide synthase inhibitor: A novel marker of atherosclerosis. Circulation 99 9 (1999) 1141-1146
13. Murohara T., Asahara T., Silver M., Bauters C., Masuda H., Kalka C., Kearney M., Chen D., Symes J.F., Fishman M.C., Huang P.L., and Isner J.M. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. The Journal of Clinical Investigation 101 11 (1998) 2567-2578
14. Ravani P., Tripepu G., Mallberti F., Testa S., Mallamaci F., and Zoccali C. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: A competing risks modeling approach. Journal of the American Society of Nephrology 16 8 (2005) 2449-2455
15. Schnabel R., Blankenberg S., Lubos E., Lackner K.J., Rupprecht H.J., Espinola-Klein C., Jachmann N., Post F., Peetz D., Bickel C., Cambien F., Tire L., and Munzel T. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: Results from the AtheroGene Study. Circulation Research 97 5 (2005) e53-59
16. Shimizu A., Kitamura H., Masuda Y., Ishizaki M., Sugisaki Y., and Yamanaka N. Rare glomerular capillary regeneration and subsequent capillary regression with endothelial cell apoptosis in progressive glomerulonephritis. The American Journal of Pathology 151 5 (1997) 1231-1239
17. Smith C.L., Birdsey G.M., Anthony S., Arrigoni F.I., Leiper J.M., and Vallance P. Dimethylarginine dimethylaminohydrolase activity modulates ADMA levels, VEGF expression, and cell phenotype. Biochemical and Biophysical Research Communications 308 4 (2003) 984-989
18. Tamaki K., Okuda S., Ando T., Iwamoto T., Nakayama M., and Fujishima M. TGF-beta 1 in glomerulosclerosis and interstitial fibrosis of adriamycin nephropathy. Kidney International 45 2 (1994) 525-536
19. Tarnow L., Hovind P., Teerlink T., Stehouwer C.D., and Parving H.H. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care 27 3 (2004) 765-769
20. Ueda S., Kato S., Matsuoka H., Kimoto M., Okuda S., Morimatsu M., and Imaizumi T. Regulation of cytokine-induced nitric oxide synthesis by asymmetric dimethylarginine: Role of dimethylarginine dimethylaminohydrolase. Circulation Research 92 2 (2003) 226-233
21. Ueda S., Yamagishi S., Matsumoto Y., Fukami K., and Okuda S. Asymmetric dimethylarginine (ADMA) and cardiovascular disease. Clinical and Experimental Nephrology 11 2 (2007) 115-121
22. Valkonen V.P., Paiva H., Salonen J.T., Lakka T.A., Lehtimaki T., Laakso S., and Laaksonen R. Risk of acute coronary event and serum concentration of asymmetrical dimethylarginine. Lancet 358 9299 (2001) 2127-2128
23. Vallance P., Leone A., Calver A., Collier J.J., and Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339 8793 (1992) 572-575
24. Zatz R., and Baylis C. Chronic nitric oxide inhibition model six years on. Hypertension 32 6 (1998) 958-964
25. Zoccali C., Bode-Böger S.M., Mallamaci F., Benedetto F., Tripepi G., Malatino L., Cataliotti A., Bellanuova I., Fermo I., Frolich J., and Boger R.H. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: A prospective study. Lancet 358 9299 (2001) 2113-2117